Niagen Bioscience (NAGE) Cash from Operations (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Cash from Operations data on file, last reported at 1194000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 115.15% year-over-year to 1194000.0 in Q1 2026; TTM through Mar 2026 was 4427000.0, a 77.52% decrease from a year earlier, with the FY2025 full-year figure at 13504000.0, up 11.52% from the prior year.
• Cash from Operations for Q1 2026 stood at 1194000.0, down from 704000.0 in the prior quarter.
• Over the last five years, Cash from Operations for NAGE reached as high as 8583000.0 in Q4 2024 and fell as low as 7198000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 966941.18 across 5 years, with a median of 649000.0 in 2023.
• Across the five-year window, Cash from Operations soared 2572.2% in 2025 and plunged 115.15% in 2026, its largest moves.
• Year by year, Cash from Operations stood at 328000.0 in 2022, then soared by 297.87% to 649000.0 in 2023, then soared by 1222.5% to 8583000.0 in 2024, then sank by 91.8% to 704000.0 in 2025, then sank by 269.6% to 1194000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 1194000.0 in Q1 2026, 704000.0 in Q4 2025, and 3700000.0 in Q3 2025.